Peachtree Corners, Georgia, USA, November 10, 2026
IMVIONIX Inc. has acquired the exclusive commercial rights to BEOVU® (brolucizumab-dbll) in the United States and Canada from Novartis, marking the official launch of the privately held ophthalmology biotechnology company. The transaction gives IMVIONIX responsibility for commercializing the retinal therapy in two major North American markets and establishes its position as a commercial-stage company focused on eye diseases. BEOVU® is an established anti-vascular endothelial growth factor (anti-VEGF) treatment approved in both countries for neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME). These retinal conditions can cause progressive visual impairment and are important causes of vision loss. Under the agreement, IMVIONIX will become the marketing authorization holder for BEOVU® in the United States and Canada. The financial terms of the transaction were not disclosed. The acquisition represents the company’s first strategic transaction and supports its stated mission of improving access to retinal therapies for patients and physicians.
Acquisition Establishes IMVIONIX as a Commercial-Stage Company
The acquisition of BEOVU® marks an important step in the formation of IMVIONIX, a company established in 2025 to identify, develop and commercialize therapies for retinal diseases. The company was founded by former executive leaders of Alimera Sciences, including Rick Eiswirth, Jason Werner, Todd Wood and Elliot Maltz, in collaboration with Caligan Partners LP and Velan Capital. According to the announcement, the founding team brings a combined 60 years of ophthalmology experience, including experience in developing and commercializing retinal therapies. IMVIONIX aims to build a focused commercial platform serving retina specialists and patients by concentrating on medicines that address important treatment needs in ophthalmology. The acquisition of BEOVU® provides the company with an established product rather than requiring it to begin commercial operations with an early-stage investigational candidate. The transaction was supported by Caligan Partners LP and its investors. IMVIONIX Chief Executive Officer and founder Rick Eiswirth said the company was established to help proven retinal therapies reach physicians and patients who may benefit from them. He described the BEOVU® acquisition as an example of the commercial opportunities the company intends to pursue as it develops its retina-focused business.
BEOVU® Targets Wet AMD and Diabetic Macular Edema
BEOVU® (brolucizumab-dbll) is a humanized single-chain antibody fragment that inhibits vascular endothelial growth factor (VEGF). VEGF plays a central role in abnormal blood vessel growth and increased vascular permeability associated with several retinal diseases. By inhibiting this pathway, BEOVU® is designed to help control disease activity in the eye. The medicine is administered through an intravitreal injection, meaning it is delivered directly into the vitreous cavity of the eye by a qualified healthcare professional. In the United States and Canada, its approved indications include neovascular or wet AMD and DME. Wet AMD involves abnormal blood vessel growth beneath the retina, which can leak fluid or blood and damage central vision. DME occurs when fluid accumulates in the macula, the central part of the retina responsible for detailed vision, in people with diabetes. Both conditions can have a substantial impact on patients’ daily activities and visual independence. Although BEOVU® is already approved in these markets, the announcement does not represent a new FDA approval or an expansion of its indications. Instead, it concerns the transfer of exclusive commercial rights and marketing authorization responsibilities from Novartis to IMVIONIX.
Advertisement
Commercial Strategy Focuses on Retinal Disease Treatment
With the acquisition completed, IMVIONIX plans to apply its ophthalmology experience and commercial capabilities to the continued marketing of BEOVU® in the United States and Canada. The company believes a dedicated retina-focused organization can strengthen engagement with specialists and support the availability of established therapies. The transaction also provides a foundation for its broader strategy of identifying and commercializing medicines that address unmet needs in retinal care. While the company has announced its official launch, its future growth will depend on execution of its commercial strategy, relationships with healthcare professionals and the ability to build a sustainable ophthalmology portfolio. BEOVU® carries important safety considerations, including risks of endophthalmitis, retinal detachment, retinal vasculitis and retinal vascular occlusion, as well as increased intraocular pressure and potential arterial thromboembolic events. Patients should promptly report symptoms such as eye pain, changes in vision or other signs of serious ocular complications. Treatment decisions and monitoring should follow the approved prescribing information and the judgment of qualified eye-care specialists. Overall, the acquisition gives IMVIONIX an established entry point into the North American retinal therapeutics market and highlights continued commercial activity in ophthalmology drug development and commercialization.
Source: IMVIONIX, Novartis press release
